Schellhorn out, Emerson in as Monteris CEO Monteris Medical said last week it tapped ex-Galil Medical prez & CEO Martin Emerson as its new president and chief executive officer, replacing John Schellhorn who left earlier this year. Emerson spent 8 years as prez & CEO of Galil Medical, which was acquired in June this year […]
McKesson Corp.
Ex-ConMed exec is Interventional Spine’s new Darling | Personnel Moves
Interventional Spine said it has tagged ex-ConMed executive and 25-year medical veteran Joseph Darling as its new vice president and COO. Darling spent 7 years with ConMed, serving as the COO, executive veep and prez of ConMed Linvatec until February this year. Before his time at ConMed, Darling worked with Smith & Nephew, Wyeth-Ayerst Pharmaceuticals, Baxter […]
McKesson dodges Medicare fraud charges
FDA puts highest-risk label on McKesson’s anesthesia system recall
Updated March 20, 2014, at 3:15 p.m. with comments from McKesson
White House has missed half of ACA deadlines | MassDevice.com On Call

MASSDEVICE ON CALL — During the 1st 3 years of Affordable Care Act implementation, the Obama administration has failed to meet half of its mandatory deadlines, according to a new report from the non-partisan Congressional Research Service.
Study: Abbott, Johnson & Johnson park billions in offshore tax havens
McKesson to pay $2B for PSS World Medical | Wall Street Beat

McKesson (NYSE:MCK) agreed to pay $29 per share for PSS World Medical (NSDQ:PSSI) and its medical supplies business in a deal worth $2.1 billion.
Abiomed: Medicare coverage decision unlikely for Impella | Wall Street Beat
Supreme Court denies ex-McKesson CEO’s appeal


The Supreme Court refused to review the conviction of former McKesson (NYSE:MCK) chairman & CEO Charles McCall in an accounting scandal, meaning his 10-year prison sentence will stand.
The high court provided no comment on the denial. San Francisco, Calif.-based McKesson is the largest drug distributor in the U.S., and also deals in healthcare information technology products.
Shire adds Pervasive Therapeutics to regenerative portfolio | Wall Street Beat
Fujifilm closes $1B SonoSite deal | Wall Street Beat





Fujifilm Holdings (TSE:4901) said it closed its $54-per-share acquisition of SonoSite (NSDQ: SONO).